Synopsis
Synopsis
0
JDMF
0
EU WC
0
KDMF
0
FDA Orange Book
0
Europe
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2,6-dichloro-alpha-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3h)-yl)benzeneacetonitrile
2. Clinacox
3. R 64433
4. R-64433
1. 101831-37-2
2. Clinacox
3. Vecoxan
4. Nuoqiu
5. 2-(4-chlorophenyl)-2-[2,6-dichloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]acetonitrile
6. 2-(4-chlorophenyl)-2-(2,6-dichloro-4-(3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3h)-yl)phenyl)acetonitrile
7. R-64433
8. R64,433
9. Nsc-759642
10. Diclazuril For Veterinary Use
11. K110k1b1ve
12. Ncgc00168785-01
13. P-64433
14. (p-chlorophenyl)(2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-as-triazin-2(3h)-yl)phenyl)acetonitrile
15. R-64-433
16. Diclazurilo
17. Diclazurilum
18. 2,6-dichloro-alpha-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3h)-yl)benzeneacetonitrile
19. 2,6-dichloro-alpha-(4-chlorophenyl)-4-[4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3h)-yl]benzeneacetonitrile
20. Dczl
21. Diclazurilum [latin]
22. Diclazurilo [spanish]
23. Sr-05000001484
24. Unii-k110k1b1ve
25. Diclazuril [usan:usp:inn:ban]
26. Drg-0079
27. Diclazuril [mi]
28. Diclazuril (usp/inn)
29. Diclazuril [inn]
30. Diclazuril [usan]
31. Diclazuril [mart.]
32. Diclazuril [usp-rs]
33. Dsstox_cid_26787
34. Dsstox_rid_81905
35. Dsstox_gsid_46787
36. Schembl126138
37. Chembl284733
38. Diclazuril [green Book]
39. Dtxsid4046787
40. Chebi:95118
41. Diclazuril For System Suitability
42. Diclazuril [usp Monograph]
43. Hms2089n18
44. Hms3655d11
45. Hms3715d21
46. Pharmakon1600-01502348
47. Amy40398
48. Bcp12257
49. Hy-b0357
50. Tox21_112645
51. Bdbm50088493
52. Mfcd00867203
53. Nsc759642
54. Stl135982
55. Akos005746928
56. Ccg-213044
57. Db11398
58. Ks-5064
59. Nsc 759642
60. Sb18820
61. Ncgc00168785-02
62. Ncgc00168785-03
63. Ac-12108
64. Ac-32608
65. Cas-101831-37-2
66. D5457
67. Ft-0603078
68. Sw199606-2
69. D03794
70. Diclazuril, Vetranal(tm), Analytical Standard
71. T70016
72. Ab01562968_01
73. Ab01562968_02
74. 831d372
75. A800467
76. Diclazuril For Veterinary Use [ep Monograph]
77. J-000501
78. Q5273856
79. Sr-05000001484-1
80. Sr-05000001484-2
81. Diclazuril 100 Microg/ml In Acetonitrile:dimethyl Sulfoxide
82. Diclazuril, United States Pharmacopeia (usp) Reference Standard
83. 2-[4-(4-chloro-alpha-cyanobenzyl)-3,5-dichlorophenyl]-1,2,4-triazine-3,5(2h,4h)-dione
84. Diclazuril For System Suitability, European Pharmacopoeia (ep) Reference Standard
85. (4-chlorophenyl)[2,6-dichloro-4-(3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3h)-yl)phenyl]acetonitrile
86. 2,6-dichloro-.alpha.-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3h)-yl)benzeneacetonitrile
87. 2,6-dichloro-alpha-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3h)-yl)-benzeneacetonitrile
88. 2-(4-chlorophenyl)-2-[2,6-dichloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]acetonitrile;diclazuril
89. Benzeneacetonitrile, 2,6-dichloro-.alpha.-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3h)-yl)-
Molecular Weight | 407.6 g/mol |
---|---|
Molecular Formula | C17H9Cl3N4O2 |
XLogP3 | 4.1 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 3 |
Exact Mass | 405.979109 g/mol |
Monoisotopic Mass | 405.979109 g/mol |
Topological Polar Surface Area | 85.6 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 629 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Coccidiostats
Agents useful in the treatment or prevention of COCCIDIOSIS in man or animals. (See all compounds classified as Coccidiostats.)
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8218
Submission : 1989-08-18
Status : Active
Type : II
Certificate Number : R1-CEP 2014-164 - Rev 02
Issue Date : 2023-04-14
Type : Chemical
Substance Number : 1718
Status : Valid
NDC Package Code : 59852-616
Start Marketing Date : 2021-04-07
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
Certificate Number : R0-CEP 2019-083 - Rev 02
Issue Date : 2023-05-02
Type : Chemical
Substance Number : 1718
Status : Valid
NDC Package Code : 86055-0013
Start Marketing Date : 2018-12-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
VMF Number : 6287
Submission : 2018-12-31
Status : Active
Type : II
Certificate Number : CEP 2018-234 - Rev 04
Issue Date : 2025-02-24
Type : Chemical
Substance Number : 1718
Status : Valid
NDC Package Code : 51943-118
Start Marketing Date : 2023-05-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
VMF Number : 6288
Submission : 2019-01-02
Status : Active
Type : II
Certificate Number : R1-CEP 2003-107 - Rev 03
Issue Date : 2013-02-26
Type : Chemical
Substance Number : 1718
Status : Withdrawn by Holder
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8218
Submission : 1989-08-18
Status : Active
Type : II
About the Company : Alivira Animal Health Limited has emerged as India's largest and 1st Global integrated animal health company specialising in manufacturing of Active Pharmaceutical Ingredients (API...
About the Company : Anhui Sinotech Industrial Co.,Ltd is specially engaged in international marketing of food/feed additive,pesticides and chemicals. We are devoted ourselves to make the life better,a...
About the Company : BOC Sciences is a brand of BOCSCI Inc. We leverage our wide spectrum of business in the fields of development, manufacturing, marketing, and distribution to help you make best-info...
About the Company : HANGZHOU THINK CHEMICAL CO., LTD. (THINKCHEM) is an integrative corporation of trade, research and contract manufacture. With about ten years of business experiences on the marketi...
About the Company : HENGDIAN GROUP was established in 1975, till now it has become a transnational,conglomerate group and been one of the largest private-owned enterprises in China. The Pharmaceutical...
About the Company : Indian Drugs And Chemicals has a wealth of knowledge & expertise that’s incomparable. We utilize this experience to provide both companies & individuals with immersible quality p...
About the Company : Omshri Labs is a privately held specialty chemicals company with corporate headquarters in Indore, Madhya Pradesh. Our company is a leader in chemical technology for Active Pharmac...
About the Company : QINGDAO QINGMEI BIOTECH(hereinafter referred to as Qingmei) is a specialized pharmaceutical company founded by DAYON INTERNATIONAL HOLDING LIMITED, which is to expand international...
About the Company : As a wholly foreign owned enterprise, Zhejiang Guobang Pharmaceutical Co., Ltd. is located in Shangyu Industrial Park, Hangzhou Bay, Zhejiang province and situated in the very cent...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Vecoxan joins Elanco’s previously announced Osurnia® and Capstar® divestitures, and divestiture of European Economic Area and U.K.
Lead Product(s): Diclazuril,Methyl 4-Hydroxybenzoate,Propyl 4-Hydroxybenzoate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Merck & Co
Deal Size: $55.0 million Upfront Cash: $55.0 million
Deal Type: Agreement February 19, 2020
Lead Product(s) : Diclazuril,Methyl 4-Hydroxybenzoate,Propyl 4-Hydroxybenzoate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : $55.0 million
Deal Type : Agreement
Elanco Signs Agreement with Merck Animal Health
Details : Vecoxan joins Elanco’s previously announced Osurnia® and Capstar® divestitures, and divestiture of European Economic Area and U.K.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $55.0 million
February 19, 2020
Regulatory Info :
Registration Country : Canada
Brand Name : CLINACOX 0.5%
Dosage Form : DRUG PREMIX
Dosage Strength : 5G/Kg
Packaging : 20KG
Approval Date :
Application Number : 2246048
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Egypt
Brand Name : Diclosol
Dosage Form : Oral Solution
Dosage Strength : 10MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Egypt
Regulatory Info :
Registration Country : Egypt
Brand Name : Diclomix
Dosage Form : Premix
Dosage Strength : 2MG/GM
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Egypt
Regulatory Info :
Registration Country : Canada
Brand Name : CLINACOX 0.5%
Dosage Form : DRUG PREMIX
Dosage Strength : 5G/Kg
Packaging : 20KG
Approval Date :
Application Number : 2246048
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Egypt
Brand Name : Diclosol
Dosage Form : Oral Solution
Dosage Strength : 10MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Egypt
Packaging :
Regulatory Info :
Dosage : Oral Solution
Dosage Strength : 10MG/ML
Brand Name : Diclosol
Approval Date :
Application Number :
Registration Country : Egypt
Regulatory Info :
Registration Country : Egypt
Brand Name : Diclomix
Dosage Form : Premix
Dosage Strength : 2MG/GM
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Egypt
Packaging :
Regulatory Info :
Dosage : Premix
Dosage Strength : 2MG/GM
Brand Name : Diclomix
Approval Date :
Application Number :
Registration Country : Egypt
Related Excipient Companies
Excipients by Applications
Market Place
Reply
20 Aug 2021
Reply
22 Mar 2021
Reply
18 Mar 2021
Reply
16 Oct 2018
Patents & EXCLUSIVITIES
Patent Expiration Date : 2005-11-01
Date Granted :
Brand Name :
Patent Number : 1244024
Filing Date :
Strength per Unit :
Dosage Form :
Human Or VET :
Route of Administration :
Patent Expiration Date : 2005-11-01
Date Granted :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
REF. STANDARDS & IMPURITIES
Diclazuril for system suitability
CAS Number : 101831-37-2
Quantity Per Vial : 20 mg
Sale Unit : 1
Order Code : Y0000259
Batch No : 1
Price (€) : 79
Storage : +5°C ± 3°C
Diclazuril for veterinary use - reference spectrum
CAS Number : n/a
Quantity Per Vial : n/a
Sale Unit : 1
Order Code : Y0000264
Batch No : 1
Price (€) : 79
Storage :
CAS Number : 101831-37-2
Quantity Per Vial : 200
Sale Unit : mg
Price : $245.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1188560 / F0H416
Diclazuril System Suitability Mixture (50 mg)
CAS Number :
Quantity Per Vial : 50
Sale Unit : mg
Price : $767.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1188571 / F0H404
ABOUT THIS PAGE
29
PharmaCompass offers a list of Diclazuril API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Diclazuril manufacturer or Diclazuril supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Diclazuril manufacturer or Diclazuril supplier.
PharmaCompass also assists you with knowing the Diclazuril API Price utilized in the formulation of products. Diclazuril API Price is not always fixed or binding as the Diclazuril Price is obtained through a variety of data sources. The Diclazuril Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Diclazuril manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Diclazuril, including repackagers and relabelers. The FDA regulates Diclazuril manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Diclazuril API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Diclazuril manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Diclazuril supplier is an individual or a company that provides Diclazuril active pharmaceutical ingredient (API) or Diclazuril finished formulations upon request. The Diclazuril suppliers may include Diclazuril API manufacturers, exporters, distributors and traders.
click here to find a list of Diclazuril suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Diclazuril DMF (Drug Master File) is a document detailing the whole manufacturing process of Diclazuril active pharmaceutical ingredient (API) in detail. Different forms of Diclazuril DMFs exist exist since differing nations have different regulations, such as Diclazuril USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Diclazuril DMF submitted to regulatory agencies in the US is known as a USDMF. Diclazuril USDMF includes data on Diclazuril's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Diclazuril USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Diclazuril suppliers with USDMF on PharmaCompass.
A Diclazuril CEP of the European Pharmacopoeia monograph is often referred to as a Diclazuril Certificate of Suitability (COS). The purpose of a Diclazuril CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Diclazuril EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Diclazuril to their clients by showing that a Diclazuril CEP has been issued for it. The manufacturer submits a Diclazuril CEP (COS) as part of the market authorization procedure, and it takes on the role of a Diclazuril CEP holder for the record. Additionally, the data presented in the Diclazuril CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Diclazuril DMF.
A Diclazuril CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Diclazuril CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Diclazuril suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Diclazuril as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Diclazuril API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Diclazuril as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Diclazuril and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Diclazuril NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Diclazuril suppliers with NDC on PharmaCompass.
Diclazuril Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Diclazuril GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Diclazuril GMP manufacturer or Diclazuril GMP API supplier for your needs.
A Diclazuril CoA (Certificate of Analysis) is a formal document that attests to Diclazuril's compliance with Diclazuril specifications and serves as a tool for batch-level quality control.
Diclazuril CoA mostly includes findings from lab analyses of a specific batch. For each Diclazuril CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Diclazuril may be tested according to a variety of international standards, such as European Pharmacopoeia (Diclazuril EP), Diclazuril JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Diclazuril USP).